{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:50:28Z","timestamp":1791406228240,"version":"4.3.3"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32525049"],"award-info":[{"award-number":["32525049"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20259"],"award-info":[{"award-number":["U23A20259"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.celrep.2026.118068","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:38:36Z","timestamp":1790890716000},"page":"118068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lacticaseibacillus rhamnosus GG enhances gefitinib efficacy and reduces treatment-related toxicity via propionyl-L-carnitine regulation"],"prefix":"10.1016","volume":"45","author":[{"given":"Siyuan","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2026.118068_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.celrep.2026.118068_bib2","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/S0140-6736(26)00966-9","article-title":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China","volume":"407","author":"Lu","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.celrep.2026.118068_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41392-024-01927-9","article-title":"Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.celrep.2026.118068_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103669","article-title":"Efficiency and safety of sintilimab-based induction therapy in potentially resectable stage III non-small cell lung cancer (LungMate-009): an open-label, phase 2 trial","volume":"90","author":"Ge","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.celrep.2026.118068_bib5","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.celrep.2026.118068_bib6","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or Carboplatin\u2013Paclitaxel in Pulmonary Adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.celrep.2026.118068_bib7","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.celrep.2026.118068_bib8","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.chom.2026.06.001","article-title":"Gut microbiota alters drug metabolism and therapeutic outcomes","volume":"34","author":"Guo","year":"2026","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.celrep.2026.118068_bib9","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41557-025-01789-w","article-title":"Activity of GPCR-targeted drugs influenced by human gut microbiota metabolism","volume":"17","author":"Wu","year":"2025","journal-title":"Nat. Chem."},{"key":"10.1016\/j.celrep.2026.118068_bib10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-019-1291-3","article-title":"Mapping human microbiome drug metabolism by gut bacteria and their genes","volume":"570","author":"Zimmermann","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.118068_bib11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1124\/dmd.121.000669","article-title":"Exploring Drug Metabolism by the Gut Microbiota: Modes of Metabolism and Experimental Approaches","volume":"50","author":"Dhurjad","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.celrep.2026.118068_bib12","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","article-title":"The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic","volume":"11","author":"Hill","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.celrep.2026.118068_bib13","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1038\/s41467-026-72592-5","article-title":"Probiotics mitigate non-antibiotic drug-induced dysbiosis via protein homology-driven competitive binding","volume":"17","author":"Feng","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.118068_bib14","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.cell.2023.05.007","article-title":"High-resolution analyses of associations between medications, microbiome, and mortality in cancer patients","volume":"186","author":"Nguyen","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.118068_bib15","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.118068_bib16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.scib.2025.12.046","article-title":"Calenduloside E produced by Bifidobacterium animalis B960 increases glibenclamide efficacy and alleviates drug-induced adverse effects in a type 2 diabetes model","volume":"71","author":"Shen","year":"2026","journal-title":"Sci. Bull."},{"key":"10.1016\/j.celrep.2026.118068_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/1471-2180-11-232","article-title":"A historical and proteomic analysis of botulinum neurotoxin type\/G","volume":"11","author":"Terilli","year":"2011","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.celrep.2026.118068_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.celrep.2026.118068_bib19","doi-asserted-by":"crossref","first-page":"8117","DOI":"10.1200\/jco.2014.32.15_suppl.8117","volume":"32","author":"Yoshioka","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.celrep.2026.118068_bib20","article-title":"Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis","volume":"367","author":"Zhao","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.celrep.2026.118068_bib21","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or Chemotherapy for Non\u2013Small-Cell Lung Cancer with Mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.celrep.2026.118068_bib22","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-472784","article-title":"Navigating First-Line Treatment Options for Patients With Epidermal Growth Factor Receptor\u2013Positive Non\u2013Small Cell Lung Cancer","volume":"45","author":"La Cava","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.celrep.2026.118068_bib23","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaoncol.2018.1395","article-title":"Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non\u2013Small Cell Lung Cancer","volume":"4","author":"Aguiar","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.celrep.2026.118068_bib24","series-title":"The Selection and Use of Essential Medicines, 2025: WHO Model List of Essential Medicines","year":"2025"},{"key":"10.1016\/j.celrep.2026.118068_bib25","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.cell.2020.05.001","article-title":"Personalized Mapping of Drug Metabolism by the Human Gut Microbiome","volume":"181","author":"Javdan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.118068_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104197","article-title":"Effects of microbiota on anticancer drugs: Current knowledge and potential applications","volume":"83","author":"Huang","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.celrep.2026.118068_bib27","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/s44161-023-00365-0","article-title":"Disrupted propionate metabolism evokes transcriptional changes in the heart by increasing histone acetylation and propionylation","volume":"2","author":"Park","year":"2023","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.celrep.2026.118068_bib28","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s42003-024-06362-8","article-title":"Fasting alleviates metabolic alterations in mice with propionyl-CoA carboxylase deficiency due to Pcca mutation","volume":"7","author":"He","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.celrep.2026.118068_bib29","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1053\/j.gastro.2022.10.018","article-title":"Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy","volume":"164","author":"Chrysostomou","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.celrep.2026.118068_bib30","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/ismej.2015.151","article-title":"Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants","volume":"10","author":"Berni Canani","year":"2016","journal-title":"ISME J."},{"key":"10.1016\/j.celrep.2026.118068_bib31","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/gutjnl-2020-323426","article-title":"Lactobacillus rhamnosus GG induces cGAS\/STING- dependent type I interferon and improves response to immune checkpoint blockade","volume":"71","author":"Si","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.celrep.2026.118068_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123848","article-title":"Chemo-immunotherapeutic potential of Lactobacillus rhamnosus GG and its bioengineering for cancer therapy","volume":"328","author":"Liu","year":"2026","journal-title":"Biomaterials"},{"key":"10.1016\/j.celrep.2026.118068_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107275","article-title":"Lactobacillus rhamnosus GG ameliorates triptolide-induced liver injury through modulation of the bile acid-FXR axis","volume":"206","author":"Hu","year":"2024","journal-title":"Pharmacol. Res."}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726011472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726011472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:54:26Z","timestamp":1791402866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124726011472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2211124726011472"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2026.118068","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lacticaseibacillus rhamnosus GG enhances gefitinib efficacy and reduces treatment-related toxicity via propionyl-L-carnitine regulation","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2026.118068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118068"}}